Brief: Anixa Biosciences Announces Treatment Of Second Patient In Fourth Cohort Of Ovarian Cancer Car-T Clinical Trial
18/08/2025 15:17
Aug 18 (Reuters) - Anixa Biosciences Inc ANIX.O: ANIXA BIOSCIENCES ANNOUNCES TREATMENT OF SECOND PATIENT IN FOURTH COHORT OF OVARIAN CANCER CAR-T CLINICAL TRIAL ANIXA BIOSCIENCES: THERAPY CONTINUES TO DEMONSTRATE FAVORABLE SAFETY PROFILE EVEN AT SIGNIFICANTLY HIGHER CELL DOSES Source text: ID:nPn1zbYWra Further company coverage: ANIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine